Discover undervalued stocks with Eulerpool.

Subscribe for $2

Biocept Stock BIOC

Price

0
Today +/-
-0
Today %
-0 %

Biocept stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Biocept stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Biocept stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Biocept stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Biocept's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Biocept Stock Price History

DateBiocept Price
2/6/20250 undefined
2/6/20250.43 undefined
3/5/20240.13 undefined

Biocept Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Biocept, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biocept from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biocept’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Biocept. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Biocept’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Biocept’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biocept’s growth potential.

Biocept Revenue, EBIT and net profit per share

DateBiocept RevenueBiocept EBITBiocept Net Income
2026e21.63 M undefined-3.19 M undefined-8.45 M undefined
2025e21.91 M undefined-17.27 M undefined-15.41 M undefined
2024e6.6 M undefined-23.53 M undefined-25.02 M undefined
2023e2.53 M undefined-24.44 M undefined-100.64 M undefined
202225.86 M undefined-31.98 M undefined-32.09 M undefined
202161.25 M undefined-2.41 M undefined-2.82 M undefined
202027.46 M undefined-15.47 M undefined-17.81 M undefined
20195.53 M undefined-23.06 M undefined-25.26 M undefined
20183.25 M undefined-24.26 M undefined-25.21 M undefined
20175.07 M undefined-21.17 M undefined-21.61 M undefined
20163.22 M undefined-18.03 M undefined-18.4 M undefined
2015610,000 undefined-16.41 M undefined-16.95 M undefined
2014130,000 undefined-13.87 M undefined-15.87 M undefined
2013130,000 undefined-7.94 M undefined-9.23 M undefined
2012110,000 undefined-10.5 M undefined-12.26 M undefined
20110 undefined-12.27 M undefined-13.63 M undefined

Biocept Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
2011201220132014201520162017201820192020202120222023e2024e2025e2026e
000003535276125262121
------66.67-40.0066.67440.00125.93-59.02-92.00200.00250.00-
------100.00-80.00-200.00-100.0022.2237.70-8.00-100.00-33.33-9.52-9.52
0-1-2-2-3-3-4-6-5623-20000
-13-12-9-15-16-18-21-25-25-17-2-32-100-25-15-8
--7.69-25.0066.676.6712.5016.6719.05--32.00-88.241,500.00212.50-75.00-40.00-46.67
00000.020.030.090.282.0711.850.490.570000
- - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Biocept Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Biocept is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (k)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (k)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
201120122013201420152016201720182019202020212022
                       
0.440.190.075.368.824.612.153.429.314.3728.8612.9
0.010.020.010.010.030.131.191.573.5314.1413.792.15
000000000000
00.060.090.190.350.550.50.590.771.932.650.76
0.370.310.80.340.440.480.420.430.32.150.390.54
0.820.580.975.99.645.774.266.0113.932.5945.6916.34
0.980.620.360.660.951.813.122.743.8414.4314.2714.14
000000000000
000000000000
000000000000
000000000000
2702700000000430456386
1.250.890.360.660.951.813.122.743.8414.8614.7314.53
2.071.471.336.5610.597.587.388.7517.7447.4560.4230.87
                       
00100000010022
85.5585.8109.96138.07158.93174.29196.54223.5256.91287.22303.83307.3
-100.93-113.19-122.42-138.29-155.24-173.64-195.25-220.46-245.72-263.53-266.35-298.44
000000000000
000000000000
-15.38-27.39-12.45-0.223.690.651.293.0411.223.6937.488.86
1.031.391.540.640.630.961.272.042.018.367.251.52
1.23.352.240.70.971.161.751.932.823.173.442.77
0.920.982.14000000000
12.3521.887.40.030.040.080.0600000.12
0000.061.72.21.580.640.720.961.081.1
15.527.613.321.433.344.44.664.615.5512.4911.775.51
1.660.7504.82.931.91.150.990.971.461.431.2
000000000000
0.270.510.460.550.620.620.270.1109.819.7415.31
1.931.260.465.353.552.521.421.10.9711.2711.1616.51
17.4328.8613.786.786.896.926.085.716.5223.7622.9422.01
2.051.471.336.5610.587.577.378.7517.7247.4560.4230.87
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Biocept provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Biocept's financial health and stability.

Assets

Biocept's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Biocept must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Biocept after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Biocept's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (k)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
-13-12-9-15-16-18-21-24-25-17-2-32
0000000001,0001,0001,000
000000000000
010-20000-1-6013
122311102353
000000000000
000000000000
-10-8-6-14-15-15-19-22-23-193-13
000000-1000-10
000000-1000-10
000000000000
000000000000
1086-20-1-2-10-1-1-2
00022191321253027140
10862018111823292512-1
------------
000000000000
-10053-4-215514-15
-11.28-8.62-6.2-14.97-15.32-16.18-21.05-22.51-23.79-20.662.12-14.1
000000000000

Biocept stock margins

The Biocept margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biocept. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biocept.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Biocept's sales revenue. A higher gross margin percentage indicates that the Biocept retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Biocept's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Biocept's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biocept's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biocept. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biocept's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Biocept Margin History

Biocept Gross marginBiocept Profit marginBiocept EBIT marginBiocept Profit margin
2026e-9.99 %-14.74 %-39.08 %
2025e-9.99 %-78.84 %-70.36 %
2024e-9.99 %-356.39 %-379.08 %
2023e-9.99 %-967.47 %-3,984.04 %
2022-9.99 %-123.69 %-124.09 %
202138.34 %-3.93 %-4.61 %
202022.29 %-56.34 %-64.86 %
2019-98.55 %-417 %-456.78 %
2018-209.23 %-746.46 %-775.69 %
2017-84.42 %-417.55 %-426.23 %
2016-114.91 %-559.94 %-571.43 %
2015-654.1 %-2,690.16 %-2,778.69 %
2014-1,569.23 %-10,669.23 %-12,207.69 %
2013-1,692.31 %-6,107.69 %-7,100 %
2012-990.91 %-9,545.45 %-11,145.46 %
2011-9.99 %0 %0 %

Biocept Stock Sales Revenue, EBIT, Earnings per Share

The Biocept earnings per share therefore indicates how much revenue Biocept has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biocept earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biocept's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biocept’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biocept's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biocept Revenue, EBIT and net profit per share

DateBiocept Sales per ShareBiocept EBIT per shareBiocept Earnings per Share
2026e1.22 undefined0 undefined-0.48 undefined
2025e1.23 undefined0 undefined-0.87 undefined
2024e0.37 undefined0 undefined-1.41 undefined
2023e0.14 undefined0 undefined-5.66 undefined
202245.76 undefined-56.59 undefined-56.78 undefined
2021124.36 undefined-4.89 undefined-5.73 undefined
20202.32 undefined-1.31 undefined-1.5 undefined
20192.67 undefined-11.14 undefined-12.2 undefined
201811.61 undefined-86.64 undefined-90.04 undefined
201756.33 undefined-235.22 undefined-240.11 undefined
2016107.33 undefined-601 undefined-613.33 undefined
201530.5 undefined-820.5 undefined-847.5 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined

Biocept business model

Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.com.

Biocept SWOT Analysis

Strengths

• Strong expertise in liquid biopsy testing, providing a non-invasive method for cancer detection.

• Proprietary Target Selector™ technology enables efficient capture and analysis of tumor biomarkers.

• Collaborative partnerships with leading pharmaceutical companies for biomarker development.

• Well-established network of clinical laboratories ensuring reliable and timely diagnostic results.

• Dependency on a limited number of large contracts, making revenue vulnerable to contract renewals.

• High research and development costs for continuous innovation and enhancement of testing methodologies.

• Limited market presence compared to larger competitors in the molecular diagnostics industry.

• Price sensitivity among potential customers, as liquid biopsy testing may be perceived as expensive.

• Growing market demand for liquid biopsy testing due to its non-invasiveness and potential for early cancer detection.

• Emerging diagnostic partnerships and collaborations opening opportunities for expanding product portfolio.

• Increasing adoption of personalized medicine, creating a need for advanced molecular diagnostics.

• Potential to penetrate untapped markets by expanding distribution networks and strategic alliances.

• Intense competition from established players and new entrants in the liquid biopsy and molecular diagnostics space.

• Strict regulatory requirements and ongoing changes in healthcare policies may impact market accessibility.

• Rapid technological advancements increasing the risk of developing more cost-effective alternatives.

• Economic downturns and market fluctuations affecting healthcare budgets and investment in diagnostic services.

Weaknesses

• Dependency on a limited number of large contracts, making revenue vulnerable to contract renewals.

• High research and development costs for continuous innovation and enhancement of testing methodologies.

• Limited market presence compared to larger competitors in the molecular diagnostics industry.

• Price sensitivity among potential customers, as liquid biopsy testing may be perceived as expensive.

• Growing market demand for liquid biopsy testing due to its non-invasiveness and potential for early cancer detection.

• Emerging diagnostic partnerships and collaborations opening opportunities for expanding product portfolio.

• Increasing adoption of personalized medicine, creating a need for advanced molecular diagnostics.

• Potential to penetrate untapped markets by expanding distribution networks and strategic alliances.

• Intense competition from established players and new entrants in the liquid biopsy and molecular diagnostics space.

• Strict regulatory requirements and ongoing changes in healthcare policies may impact market accessibility.

• Rapid technological advancements increasing the risk of developing more cost-effective alternatives.

• Economic downturns and market fluctuations affecting healthcare budgets and investment in diagnostic services.

Opportunities

• Growing market demand for liquid biopsy testing due to its non-invasiveness and potential for early cancer detection.

• Emerging diagnostic partnerships and collaborations opening opportunities for expanding product portfolio.

• Increasing adoption of personalized medicine, creating a need for advanced molecular diagnostics.

• Potential to penetrate untapped markets by expanding distribution networks and strategic alliances.

• Intense competition from established players and new entrants in the liquid biopsy and molecular diagnostics space.

• Strict regulatory requirements and ongoing changes in healthcare policies may impact market accessibility.

• Rapid technological advancements increasing the risk of developing more cost-effective alternatives.

• Economic downturns and market fluctuations affecting healthcare budgets and investment in diagnostic services.

Threats

• Intense competition from established players and new entrants in the liquid biopsy and molecular diagnostics space.

• Strict regulatory requirements and ongoing changes in healthcare policies may impact market accessibility.

• Rapid technological advancements increasing the risk of developing more cost-effective alternatives.

• Economic downturns and market fluctuations affecting healthcare budgets and investment in diagnostic services.

Biocept Revenue by Segment

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biocept Revenue by Segment

Segmente2022202120202019
Commercial Revenues25.62 M USD---
Development Services Revenues240,000 USD---
Kits and Specimen Collection Tubes (SCTs)2,000 USD---

  • 3 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biocept Revenue by Segment

Segmente2022202120202019
Commercial test revenue-59.7 M USD23.3 M USD-

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biocept Revenue by Segment

Segmente2022202120202019
Commercial Revenues-60.93 M USD26.86 M USD5.12 M USD
Kits and blood collection tubes--420,820 USD200,012 USD
Development services-68,000 USD177,286 USD212,344 USD
Kits and specimen collection tubes-171,000 USD--

Biocept Revenue by Region

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Biocept Revenue by Segment

DateInternational
201516,027 USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Biocept Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Biocept historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Biocept shares outstanding

The number of shares was Biocept in 2024 — This indicates how many shares 565,130 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biocept earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biocept's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biocept’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biocept's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biocept stock splits

In Biocept's history, there have been no stock splits.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Biocept.

Biocept shareholders

%
Name
Stocks
Change
Date
0.76105 % The Lind Partners, LLC135,294135,2945/26/2023
0.25235 % Anson Funds Management LP.44,86144,8616/30/2023
0.13235 % Boothbay Fund Management, LLC23,52923,5296/30/2023
0.03031 % Tower Research Capital LLC5,3895,1106/30/2023
0.02959 % BlackRock Institutional Trust Company, N.A.5,261-36/30/2023
0.00152 % Group One Trading, L.P.27036/30/2023
0.00151 % JPMorgan Private Bank (United States)2682686/30/2023
0.00139 % Acadian Asset Management LLC247-2156/30/2023
0.00065 % City National Rochdale, LLC115-16/30/2023
0.00019 % Osaic Holdings, Inc.3306/30/2023
1
2
3
4
5
...
6

Biocept Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Laboratory Corp Stock
Laboratory Corp
SupplierCustomer0,690,760,570,830,44-0,63
Quest Diagnostics Stock
Quest Diagnostics
SupplierCustomer0,530,42-0,220,790,24-0,52
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,400,820,180,85-0,12-0,67
UnitedHealth Group Stock
UnitedHealth Group
SupplierCustomer0,020,73-0,53-0,63-0,81-0,80
Kadmon Holdings, Inc. Stock
Kadmon Holdings, Inc.
SupplierCustomer0,01-0,78-0,75-0,89-0,84
AstraZeneca Stock
AstraZeneca
SupplierCustomer-0,040,26-0,74-0,77-0,75-0,49
Avantor Stock
Avantor
SupplierCustomer-0,490,090,700,910,54-0,64
1

Most common questions regarding Biocept

What values and corporate philosophy does Biocept represent?

Biocept Inc represents values of innovation, quality, and commitment to improving patient care. With a corporate philosophy focused on leveraging advanced diagnostics, Biocept aims to enable oncologists to make more informed treatment decisions. By developing and commercializing proprietary liquid biopsy tests, the company helps provide actionable biomarker information for personalized medicine. Biocept embraces cutting-edge technologies, rigorous research practices, and strategic collaborations to deliver reliable and accurate results. Through their dedication to accuracy, speed, and accessibility, Biocept is streamlining the diagnosis and monitoring of cancer, ultimately facilitating better patient outcomes.

In which countries and regions is Biocept primarily present?

Biocept Inc is primarily present in the United States. As a leading molecular diagnostics company, Biocept focuses on providing advanced oncology testing services to physicians and patients nationwide. With their state-of-the-art laboratory facilities and cutting-edge technology, Biocept offers innovative liquid biopsy tests that detect and monitor various cancer biomarkers. By leveraging their expertise in circulating tumor cells and circulating tumor DNA analysis, Biocept aims to enhance cancer detection and treatment strategies, ultimately improving patient outcomes.

What significant milestones has the company Biocept achieved?

Biocept Inc has achieved significant milestones in its history. Some notable achievements of the company include the successful launch of their liquid biopsy platform, which enables the detection and monitoring of cancer through blood samples. They have also secured multiple patents related to their proprietary technology. Biocept Inc has established partnerships with renowned healthcare institutions and laboratories, further expanding their reach and impact. Additionally, the company has announced successful collaborations with pharmaceutical companies to develop precision medicine strategies. These milestones highlight Biocept Inc's commitment to innovation, research, and improving cancer diagnosis and treatment.

What is the history and background of the company Biocept?

Biocept Inc is a leading molecular diagnostics company that specializes in providing liquid biopsy tests for cancer detection and monitoring. The company was founded in 1997 and is headquartered in San Diego, California. Biocept utilizes proprietary technology to analyze circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) present in a patient's blood sample. These tests aid in early cancer detection, treatment selection, and monitoring of therapeutic effectiveness. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to advance personalized medicine and enhance patient care. Biocept Inc has gained recognition for its innovative solutions and continues to make significant contributions in the field of molecular diagnostics.

Who are the main competitors of Biocept in the market?

The main competitors of Biocept Inc in the market are companies like Guardant Health, Inc. and Genomic Health, Inc. These companies also provide molecular diagnostic testing services and solutions for cancer detection and treatment. However, what sets Biocept apart is its unique liquid biopsy technology and its ability to capture and analyze tumor cells from a simple blood sample. With its innovative and efficient testing methods, Biocept Inc remains at the forefront of the market, offering reliable and accurate diagnostic solutions to patients and healthcare providers.

In which industries is Biocept primarily active?

Biocept Inc is primarily active in the healthcare and biotechnology industries. As a leading molecular diagnostics company, Biocept specializes in providing clinically actionable information to healthcare providers, assisting in the treatment of patients with cancer. Through its proprietary liquid biopsy technology, Biocept enables the detection and monitoring of circulating tumor cells and circulating tumor DNA, aiding in the diagnosis and management of various types of cancer. With its innovative solutions and commitment to advancing personalized medicine, Biocept continues to make significant contributions to the healthcare industry.

What is the business model of Biocept?

Biocept Inc. operates as a molecular diagnostics company. Its business model revolves around developing and commercializing proprietary circulating tumor cell and circulating tumor DNA assays to provide physicians with insights for treating and monitoring cancer patients. By utilizing patented technologies, Biocept's liquid biopsy tests detect and analyze tumor-associated biomarkers from a simple blood sample. This enables healthcare providers to make informed decisions regarding the selection of targeted therapies, monitoring treatment response, and detecting the development of resistance mutations in cancer patients. Biocept aims to improve patient outcomes and contribute to advancing precision medicine in oncology.

What is the P/E ratio of Biocept 2025?

The P/E ratio cannot be calculated for Biocept at the moment.

What is the P/S ratio of Biocept 2025?

The P/S cannot be calculated for Biocept currently.

What is the Quality Investing of Biocept?

The Quality Investing for Biocept is 5/10.

What is the revenue of Biocept 2025?

The expected Biocept revenue is 21.91 M USD.

How high is the profit of Biocept 2025?

The expected Biocept profit is -15.41 M USD.

What is the business model of Biocept

Biocept Inc specializes in the development and marketing of liquid biopsy technologies and products for cancer diagnostics. The company's business model involves generating higher income and increasing profits through the sale of diagnostic tests and services for cancer medicine. Biocept Inc offers a wide range of diagnostic tests for cancer patients aimed at early detection and more accurate classification of the disease. These products range from Helix for breast and lung cancer to Pathnostics for prostate cancer, as well as a variety of tests for rare cancer types. These diagnostic tests use advanced technologies like liquid biopsy to provide patients with precise and comprehensive information about their cancer. The company has developed its technology to be able to isolate cancer cells from a small amount of blood, providing an accurate and non-invasive method for cancer diagnosis that spares patients from undergoing a biopsy. This technology allows doctors to tailor treatment more precisely and monitor the progression of the disease in an accurate manner. In addition to products, Biocept Inc also provides services for cancer patients. The company has a team of experienced medical professionals who perform the diagnostic tests and interpret the results. The results of these tests are an important basis for making decisions about the patient's further treatment. The company's focus is on delivering high-quality diagnosis to ensure the best possible care for each individual patient. In the field of medical diagnostics, Biocept Inc has established a strong competitive position. Through continuous development of its products and services, the company has built a reputation for innovative and reliable diagnostic tests in the market. The company also leverages partnerships with other companies in the healthcare industry to expand its business and introduce new products and services to the market. With its advanced technologies and high standardization measures, Biocept Inc is well positioned for collaboration with other companies. These partnerships enable faster product launches and better integration of the partners' products and services. Overall, Biocept Inc's business model is focused on generating higher income and increasing profits through the development and marketing of liquid biopsy technologies and products for cancer diagnostics. The company strives to continuously improve its products and services and introduce new partnerships to thrive in a competitive environment.

What is the Biocept dividend?

Biocept pays a dividend of 0 USD distributed over payouts per year.

How often does Biocept pay dividends?

The dividend cannot currently be calculated for Biocept or the company does not pay out a dividend.

What is the Biocept ISIN?

The ISIN of Biocept is US09072V5012.

What is the Biocept WKN?

The WKN of Biocept is A2QEQE.

What is the Biocept ticker?

The ticker of Biocept is BIOC.

How much dividend does Biocept pay?

Over the past 12 months, Biocept paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biocept is expected to pay a dividend of 0 USD.

What is the dividend yield of Biocept?

The current dividend yield of Biocept is .

When does Biocept pay dividends?

Biocept pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biocept?

Biocept paid dividends every year for the past 0 years.

What is the dividend of Biocept?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biocept located?

Biocept is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biocept kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biocept from 9/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.

When did Biocept pay the last dividend?

The last dividend was paid out on 9/26/2025.

What was the dividend of Biocept in the year 2024?

In the year 2024, Biocept distributed 0 USD as dividends.

In which currency does Biocept pay out the dividend?

The dividends of Biocept are distributed in USD.

All fundamentals about Biocept

Our stock analysis for Biocept Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocept Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.